Dr. Montaner pioneered an innovative new concept called Treatment as Prevention® (TasP®) based on the notion that providing access to HAART at the earliest point following an HIV diagnosis could dramatically reduce the spread of HIV. The Lancet published a study led by Dr. Montaner presenting evidence supporting the efficiency of TasP® in reducing new HIV cases.
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
